Moderna shares advanced after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Moderna's stock rose nearly 1.5% in morning trading. In the week following approval, Moderna said it shipped twice as many doses as it did a year earlier.